Venus Remedies Ltd

Venus Remedies Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Venus Remedies Ltd

₹ 343 5.32%
16 May - close price
venusremedies.com BSE: 526953 NSE: VENUSREM
About

Incorporated in 1989, Venus Remedies
Ltd is a research based pharmaceutical company and an injectable manufacturer[1]

Key Points

Business Overview:[1][2]
VSR is one of the largest manufacturers of meropenem antibiotics and emerging player in AMR drug in India. It offers a wide range of pharmaceutical products that cater to various therapeutic areas, including anti infective (antibiotics), antimicrobial resistance, oncology, neurology, pain management, skin
& wound care. Company has 1040+ marketing authorizations globally, 135+ patents and 180+ product basket which includes formulations such as injectables,
tablets, and topical preparations

Website BSE NSE
  • Market Cap ₹ 458 Cr.
  • Current Price ₹ 343
  • High / Low ₹ 428 / 270
  • Stock P/E 16.4
  • Book Value ₹ 370
  • Dividend Yield 0.00 %
  • ROCE 8.57 %
  • ROE 5.94 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Stock is trading at 0.93 times its book value

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 7.10% over last 3 years.
  • Earnings include an other income of Rs.28.0 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
124 142 143 140 117 156 95 168 143 195 109 167 177
112 137 129 127 109 131 85 150 131 176 97 163 158
Operating Profit 12 6 15 13 8 25 10 18 12 19 11 5 18
OPM % 10% 4% 10% 9% 7% 16% 11% 11% 8% 10% 10% 3% 10%
1 2 1 2 4 3 2 3 2 4 2 11 12
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 9 8 8 9 7 8 8 6 7 6 6 6 5
Profit before tax 5 0 8 6 5 20 5 14 8 17 7 9 25
Tax % -20% 0% 13% 8% 28% 44% 77% 31% 12% 40% 82% 61% 21%
6 0 7 5 3 11 1 10 7 11 1 4 20
EPS in Rs 4.23 0.17 5.15 3.99 2.46 8.27 0.88 7.44 5.12 7.86 0.91 2.63 14.66
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
459 531 455 407 400 372 322 335 544 597 552 596 648
339 393 366 326 349 333 289 295 490 535 492 537 594
Operating Profit 120 138 89 81 51 39 33 41 54 62 60 60 54
OPM % 26% 26% 20% 20% 13% 11% 10% 12% 10% 10% 11% 10% 8%
0 0 1 2 2 2 -3 -4 43 8 10 12 28
Interest 25 29 41 38 34 35 25 13 13 0 0 0 0
Depreciation 33 40 46 42 40 34 34 32 35 34 32 26 24
Profit before tax 63 69 3 4 -22 -28 -30 -8 49 36 38 45 58
Tax % 9% 7% -95% 52% -21% 11% -4% 24% -27% -12% 30% 36%
57 64 5 2 -17 -31 -29 -10 62 41 27 28 35
EPS in Rs 54.36 56.20 4.51 1.49 -13.84 -24.87 -23.15 -8.10 50.05 30.46 19.88 21.31 26.06
Dividend Payout % 6% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 1%
5 Years: 13%
3 Years: 3%
TTM: 15%
Compounded Profit Growth
10 Years: -8%
5 Years: 28%
3 Years: -10%
TTM: -4%
Stock Price CAGR
10 Years: 8%
5 Years: 50%
3 Years: 13%
1 Year: 12%
Return on Equity
10 Years: 2%
5 Years: 6%
3 Years: 7%
Last Year: 6%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 11 11 11 11 12 12 12 12 12 13 13 13 13
Reserves 369 450 445 426 376 350 320 311 388 427 447 474 481
271 289 321 335 312 307 298 220 51 43 42 41 41
67 84 64 70 65 82 102 100 104 97 98 98 125
Total Liabilities 718 834 841 843 765 751 733 644 556 580 601 627 660
401 439 444 452 406 389 364 289 262 241 216 219 237
CWIP 48 68 78 80 66 65 65 25 25 25 26 21 23
Investments 0 0 0 0 0 0 0 0 0 0 20 19 56
268 327 319 310 293 297 304 330 269 314 339 368 345
Total Assets 718 834 841 843 765 751 733 644 556 580 601 627 660

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
52 53 68 47 59 31 45 78 132 41 37 37
-104 -95 -67 3 -18 8 -11 -5 57 -17 -58 -8
55 40 -1 -46 -44 -39 -35 -73 -162 -9 -1 -1
Net Cash Flow 3 -2 -1 3 -4 0 -1 -0 27 14 -22 28

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 37 45 51 55 43 46 43 33 21 24 51 49
Inventory Days 178 173 194 219 226 246 286 296 129 118 132 125
Days Payable 26 38 40 38 48 52 72 77 76 47 56 45
Cash Conversion Cycle 190 180 204 236 221 240 257 252 74 95 127 129
Working Capital Days 98 115 146 179 163 144 127 166 74 85 112 120
ROCE % 15% 14% 6% 5% 2% 1% 1% 2% 8% 8% 8% 9%

Shareholding Pattern

Numbers in percentages

2 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76%
0.96% 1.13% 1.07% 1.00% 0.98% 1.03% 1.59% 1.48% 1.06% 1.18% 1.11% 1.34%
57.28% 57.11% 57.19% 57.26% 57.26% 57.21% 56.65% 56.76% 57.17% 57.06% 57.13% 56.90%
No. of Shareholders 21,18922,01522,24321,71920,49819,26719,56019,91319,61419,55719,77119,982

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings